PMID- 32565768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1687-4757 (Print)
IS  - 1687-4765 (Electronic)
VI  - 2020
DP  - 2020
TI  - PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung 
      Squamous Cell Carcinoma.
PG  - 2510951
LID - 10.1155/2020/2510951 [doi]
LID - 2510951
AB  - Previous studies showed that PPAR-gamma (PPARG) ligands might serve as potential 
      therapeutic agents for nonsmall cell lung cancer (NSCLC). However, a few studies 
      reported the specific relationship between PPARG and lung squamous cell carcinoma 
      (LSCC). Here, we made an effort to explore the relationship between PPARG and 
      LSCC. First, we used mega-analysis and partial mega-analysis to analyze the 
      effects of PPARG on LSCC by using 12 independent LSCC expression datasets (285 
      healthy controls and 375 LSCC cases). Then, literature-based molecular pathways 
      between PPARG and LSCC were established. After that, a gene set enrichment 
      analysis (GSEA) was conducted to study the functionalities of PPARG and 
      PPARG-driven triggers within the molecular pathways. Finally, another 
      mega-analysis was constructed to test the expression changes of PPARG and its 
      driven targets. The partial mega-analysis showed a significant downregulated 
      expression of PPARG in LSCC (LFC = -1.08, p value = 0.00073). Twelve diagnostic 
      markers and four prognostic markers were identified within multiple PPARG-LSCC 
      regulatory pathways. Our results suggested that the activation of PPARG 
      expression may inhibit the development and progression of LSCC through the 
      regulation of LSCC upstream regulators and downstream marker genes, which were 
      involved in tumor cell proliferation and protein 
      polyubiquitination/ubiquitination.
CI  - Copyright (c) 2020 Shunbin Shi et al.
FAU - Shi, Shunbin
AU  - Shi S
AD  - Department of Thoracic Surgery, Suzhou Ninth People's Hospital, Suzhou, Jiangsu 
      Province 215200, China.
FAU - Yu, Guiping
AU  - Yu G
AUID- ORCID: 0000-0002-6806-513X
AD  - Department of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University 
      Medical College, Jiangyin, Jiangsu Province 214400, China.
FAU - Huang, Bin
AU  - Huang B
AD  - Department of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University 
      Medical College, Jiangyin, Jiangsu Province 214400, China.
FAU - Mi, Yedong
AU  - Mi Y
AD  - Department of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University 
      Medical College, Jiangyin, Jiangsu Province 214400, China.
FAU - Kang, Yan
AU  - Kang Y
AUID- ORCID: 0000-0002-0967-7849
AD  - Department of General Surgery, Children's National Medical Center, Washington, DC 
      20010, USA.
FAU - Simon, Julia Pia
AU  - Simon JP
AD  - Neuroimaging and Informatics Institute, University of Southern California, 
      California, Los Angeles 90007, USA.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - PPAR Res
JT  - PPAR research
JID - 101269101
PMC - PMC7285416
COIS- All the authors declare no conflict of interest.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
PMCR- 2020/06/01
CRDT- 2020/06/23 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - 10.1155/2020/2510951 [doi]
PST - epublish
SO  - PPAR Res. 2020 Jun 1;2020:2510951. doi: 10.1155/2020/2510951. eCollection 2020.